Analyst Tejas Savant of Morgan Stanley maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a price target of ...

At Myriad, we’re committed to partnering with genetic counselors in an effort to make genetic testing more accessible, affordable and easier to use for all patient populations,” said Susan Manley, ...

Fintel reports that on September 19, 2024, Morgan Stanley initiated coverage of Myriad Genetics (NasdaqGS:MYGN) with a ...

Myriad Genetics, Inc. (MYGN) stock saw a modest uptick, ending the day at $28.6 which represents a slight increase of $0.70 or 2.51% from the prior close of $27.9. The stock opened at $27.94 and ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 4.00% of ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

On chromosome 1p35.2, the research identified two distinct genetic variants associated with MS risk – one specific to Native American haplotypes and the other to European haplotypes.

SOPHiA GENETICS, in collaboration with AstraZeneca, conducted a study that leveraged advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who ...

We conducted such a study of all-cause dementia and discovered a substantial genetic overlap with vascular dementia." Bernard Fongang, PhD, Assistant Professor, Bioinformatics, Glenn Biggs ...

14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for ...